Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 13/20 | 0.39 |
| ▸ | HTR2B | P41595 | 13/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20986376 | 1.00 | HTR2C (0.39) | HTR2CHTR2BPARP1HTR2AHTR3E | |
| SCHEMBL20986373 | 1.00 | HTR2C (0.39) | HTR2CHTR2BPARP1HTR2AHTR3E | |
| Hydrochloric Acid SCHEMBL16764419 | 0.98 | HTR2C (0.39) | HTR2CHTR2BPARP1HTR2AHTR3E | |
| Hydrochloric Acid SCHEMBL16764417 | 0.98 | HTR2C (0.39) | HTR2CHTR2BPARP1HTR2AHTR3E | |
| SCHEMBL16763877 | 0.92 | PARP1 (0.38) | HTR2CHTR2BPARP1HTR2AHTR3E | |
| SCHEMBL16763874 | 0.92 | PARP1 (0.38) | HTR2CHTR2BPARP1HTR2AHTR3E | |
| Hydrochloric Acid SCHEMBL21855144 | 0.90 | PARP1 (0.37) | HTR2CHTR2BPARP1HTR2AHTR3E | |
| SCHEMBL2865250 | 0.81 | HTR2C (0.39) | HTR2CHTR2BPARP1NPY5RNOS3 | |
| Trifluoroacetic Acid SCHEMBL28856904 | 0.81 | PARP1 (0.37) | HTR2CHTR2BPARP1NPY5R | |
| Bromide SCHEMBL11445492 | 0.80 | HTR2C (0.42) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190100505-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2019-04-04 | — | — | US | disclosed |
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-02-01 | — | — | US | disclosed |
| US-9656988-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656988-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160355498-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160355498-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9382246-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2016-07-05 | — | — | US | disclosed |
| US-9382246-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2016-07-05 | — | — | US | disclosed |
| WO-2015084998-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| US-20150158865-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2015-06-11 | — | — | US | disclosed |
| US-20150158865-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | HTR2C 3734/4885HTR2B 3298/4885PARP1 891/4885 |
| US-20160355498-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | HTR2C 3688/4885HTR2B 3267/4885PARP1 892/4885 |
| US-20190100505-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | HTR2C 3688/4885HTR2B 3267/4885PARP1 892/4885 |
| US-20150158865-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | HTR2C 3688/4885HTR2B 3267/4885PARP1 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.